Dr Clare Slaney
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
55 Scholarly works
10 Projects
HIGHLIGHTS
2025
Journal article
Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models
DOI: 10.1126/scitranslmed.adk06272025
Journal article
Optimised modular anti-FLAG CAR T cells for solid tumor therapy
DOI: 10.1002/cti2.700462025
Research grants (other domestic)
Rejuvenating the Lymph Nodes to Treat Breast Cancer Metastasis
2024
Journal article
Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals
DOI: 10.1002/cti2.700162024
Journal article
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
DOI: 10.1038/s41586-024-07242-12020
Research grants (ARC, NHMRC, MRFF)
Car T Cells and "A Good Beating" for Cancer Therapy
2020
Research grants (other domestic)
Car T Cells and a Good \201cbeating\201d for Breast Cancers
RECENT SCHOLARLY WORKS
2023
Journal article
YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells
DOI: 10.1038/s41467-023-37161-02023
Journal article
TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
DOI: 10.1126/scitranslmed.abk19002023
Journal article
Insights into Cancer Immunotherapies: Recent Breakthroughs, Opportunities, and Challenges
DOI: 10.3390/cancers150413222023
Journal article
Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new
DOI: 10.3389/fimmu.2022.11296232021
Journal article
Enhancing adoptive cell transfer with combination braf-mek and cdk4/6 inhibitors in melanoma
DOI: 10.3390/cancers132463422021
Journal article
Cellular networks controlling T cell persistence in adoptive cell therapy
DOI: 10.1038/s41577-021-00539-6
RECENT PROJECTS
2026
Research grants (other domestic)
Corona-Car T Cells and COVID Vaccine for Cancer Treatment
2018
Research Grant
Using Lessons From Toxic Shock Syndrome to Enhance Breast Cancer Immunotherapy